MRSA Research Today is a free monthly online journal that collates and summarizes the latest research about MRSA, including details on methicillin-resistant staphylococcus aureus, hospitals, infection, antibiotic resistance, superbugs.

Bactericidal Activity and Resistance Development Profiling of Dalbavancin.

Goldstein BP, Draghi DC, Sheehan DJ, Hogan P, Sahm DF

Focus Bio-Inova, Inc., Herndon, VA; and Pfizer Inc, Pfizer Global Pharmaceuticals, New York, N.Y; and King of Prussia, PA.

Dalbavancin, a semisynthetic lipoglycopeptide being developed to treat skin and skin structure infections (SSSI), has a half-life of 5-7 days in humans and offers promise for a convenient weekly dosing regimen. We studied the in vitro bactericidal activity of dalbavancin against target organisms, utilizing concentrations that are maintained in human blood with the proposed dosage regimen. Dalbavancin MBCs were </= 0.5 microg/ml for eight staphylococcal isolates, and for six of these strains, including one VISA, were equal to or within one doubling dilution of the MIC. Dalbavancin MICs for all three S. pyogenes strains were 0.008 microg/ml, as were the MBCs for two of the isolates. In time-kill studies conducted with a different set of seven strains (two MSSA, three MRSA, one VISA, and one S. pyogenes) all strains exhibited a >/= 3 log10 decrease in viable count when exposed to >/= 1 microg/ml of dalbavancin for 24 hours. Resistance development studies by both direct selection (frequency < 10(-10)) and serial passage failed to produce stable mutants with decreased susceptibility to dalbavancin. These observations suggest that dalbavancin will be an effective choice for the management of patients with SSSI.

Published 15 January 2007 in Antimicrob Agents Chemother.
Full-text of this article is available online (may require subscription).

© 2004-2008 MRSA Research Today. All Rights Reserved.